Institute of Fermentation Engineering, College of Biotechnology and Bioengineering, Zhejiang University of Technology, Hangzhou, PR China.
Institute of Fermentation Engineering, College of Biotechnology and Bioengineering, Zhejiang University of Technology, Hangzhou, PR China.
Biomed J. 2020 Oct;43(5):414-423. doi: 10.1016/j.bj.2020.08.006. Epub 2020 Aug 11.
Human coronaviruses (HCoVs), including severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV), and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), have been resulting in global epidemics with heavy morbidity and mortality. Unfortunately, there are currently no specific medicines that can better treat these coronaviruses. Drug repurposing is an effective and economical strategy for drug discovery from existing drugs, natural products, and synthetic compounds. In this review, the broad-spectrum antiviral activity of valinomycin (VAL), especially its activity against coronaviruses such as SARS-CoV, MERS-CoV, human coronavirus OC43 (HCoV-OC43), were summarized, it highlights that VAL has tremendous potential for use as a novel antiviral agent against SARS-CoV-2.
人类冠状病毒(HCoVs),包括严重急性呼吸综合征冠状病毒(SARS-CoV)、中东呼吸综合征冠状病毒(MERS-CoV)和严重急性呼吸综合征冠状病毒 2(SARS-CoV-2),已经导致了具有高发病率和死亡率的全球性流行。不幸的是,目前尚无专门治疗这些冠状病毒的药物。药物再利用是从现有药物、天然产物和合成化合物中发现药物的一种有效且经济的策略。在这篇综述中,总结了缬氨霉素(VAL)的广谱抗病毒活性,特别是其对 SARS-CoV、MERS-CoV、人冠状病毒 OC43(HCoV-OC43)等冠状病毒的活性,突出了 VAL 作为一种新型抗 SARS-CoV-2 抗病毒药物具有巨大的潜力。